Press Releases
-
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
INDIANAPOLIS , Aug. 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration ( FDA ) has approved Taltz ® (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis (AS), also known as radiographic
-
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
INDIANAPOLIS , Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD program to be completed in 2019.
-
Arbitration panel rules in favor of Lilly in complaint filed by Adocia
INDIANAPOLIS , Aug. 22, 2019 /PRNewswire/ -- A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY) in a claim filed by Adocia S.A. over the companies' prior collaboration on a rapid-acting insulin. The panel of three arbitrators ruled that Lilly acted
-
Lilly Announces Webcast to Discuss World Conference on Lung Cancer Presentation
INDIANAPOLIS , Aug. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at the 20 th meeting of the International Association for the Study of Lung Cancer (IASLC) World Conference
-
Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health
INDIANAPOLIS , Aug. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering digital health solutions aimed at transforming inflammatory bowel disease (IBD) care.
-
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis
- IXORA-R is the first Phase 4 head-to-head study comparing efficacy between an IL-17A inhibitor and an IL-23/p19 inhibitor using PASI 100 as the primary endpoint - INDIANAPOLIS , Aug. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Taltz ® (ixekizumab) met the primary
-
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit
INDIANAPOLIS , Aug. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lilly, confirming that the Alimta ® (pemetrexed for injection) vitamin regimen patent would be infringed by competitors that had
-
Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia
INDIANAPOLIS , Aug. 8, 2019 /PRNewswire/ -- Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health , and Apple Inc. (NASDAQ: AAPL) showed that an iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps may
-
Lilly Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services
INDIANAPOLIS , Aug. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations. Darren Carroll , senior vice president of corporate business
-
Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
-Failure to respond to migraine preventive treatments is a common occurrence; internationally it is estimated that more than 40% of patients who use migraine preventive medications have a history of failure or switching treatments(1) INDIANAPOLIS , Aug.
-
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
INDIANAPOLIS , Aug. 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration ( FDA ) has approved Taltz ® (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis (AS), also known as radiographic
-
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
INDIANAPOLIS , Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD program to be completed in 2019.
-
Arbitration panel rules in favor of Lilly in complaint filed by Adocia
INDIANAPOLIS , Aug. 22, 2019 /PRNewswire/ -- A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY) in a claim filed by Adocia S.A. over the companies' prior collaboration on a rapid-acting insulin. The panel of three arbitrators ruled that Lilly acted
-
Lilly Announces Webcast to Discuss World Conference on Lung Cancer Presentation
INDIANAPOLIS , Aug. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at the 20 th meeting of the International Association for the Study of Lung Cancer (IASLC) World Conference
-
Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health
INDIANAPOLIS , Aug. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering digital health solutions aimed at transforming inflammatory bowel disease (IBD) care.
-
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis
- IXORA-R is the first Phase 4 head-to-head study comparing efficacy between an IL-17A inhibitor and an IL-23/p19 inhibitor using PASI 100 as the primary endpoint - INDIANAPOLIS , Aug. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Taltz ® (ixekizumab) met the primary
-
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit
INDIANAPOLIS , Aug. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lilly, confirming that the Alimta ® (pemetrexed for injection) vitamin regimen patent would be infringed by competitors that had
-
Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia
INDIANAPOLIS , Aug. 8, 2019 /PRNewswire/ -- Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health , and Apple Inc. (NASDAQ: AAPL) showed that an iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps may
-
Lilly Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services
INDIANAPOLIS , Aug. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations. Darren Carroll , senior vice president of corporate business
-
Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
-Failure to respond to migraine preventive treatments is a common occurrence; internationally it is estimated that more than 40% of patients who use migraine preventive medications have a history of failure or switching treatments(1) INDIANAPOLIS , Aug.
-
Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance
- Revenue in the second quarter of 2019 grew 1 percent, driven by 6 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Basaglar, Emgality and Cyramza, contributed 13 percentage points of revenue growth and represented
-
Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Verzenio is the first and only CDK4 & 6 inhibitor in combination with fulvestrant to achieve statistically significant improvement in overall survival MONARCH 2 was a Phase 3 study including both pre/peri- and postmenopausal women whose cancer progressed following endocrine therapy INDIANAPOLIS ,
-
BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
BAQSIMI is expected to be available in U.S. pharmacies within one month INDIANAPOLIS , July 24, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and
-
Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
-Data from OVERCOME shed new light on migraine stigma by examining attitudes through the eyes of people who have not been diagnosed with migraine[1] -OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) aims to further understand the burden, stigma and barriers faced
-
Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine
-Data from OVERCOME showed that inconsistent care patterns, including high use of emergency department/urgent care settings, may be contributing to misdiagnosis, sub-optimal treatment and increased healthcare utilization(1) -OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of
-
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine
-Results showed that treatment with Emgality, when compared to placebo, resulted in lower levels of migraine-related disability and fewer restrictions on daily activities that are limited by migraine, such as relationships with family and friends, leisure time, productivity, concentration, energy
-
Lilly Announces Changes in Senior Leadership
Mike Harrington, senior vice president and general counsel, to retire at year end Christi Shaw to leave Lilly; Patrik Jonsson will be promoted to lead Lilly Bio-Medicines INDIANAPOLIS , July 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced several changes to the company's
-
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache
INDIANAPOLIS , July 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine published positive Phase 3 study results of Emgality ® (galcanezumab-gnlm) for the treatment of episodic cluster headache.
-
Lilly Confirms Date and Conference Call for Second-Quarter 2019 Financial Results Announcement
INDIANAPOLIS , July 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2019 financial results on Tuesday, July 30, 2019 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial
-
Lilly Declares Third-Quarter 2019 Dividend
INDIANAPOLIS , June 19, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2019 of $0.645 per share on outstanding common stock. The dividend is payable September 10, 2019 , to shareholders of record at the close of
-
Hurricane Season is Almost Here. Are You Ready?
Lilly, Healthcare Ready and Direct Relief Helping People Prepare for Disasters, Ensure Medicines are Available INDIANAPOLIS , May 31, 2019 /PRNewswire/ -- The 2019 Atlantic hurricane season begins June 1 . With natural disasters and extreme weather on the rise, it's critical to be prepared and
-
Lilly to Participate in Goldman Sachs Global Healthcare Conference
INDIANAPOLIS , May 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 40 th Annual Global Healthcare Conference on Wednesday, June 12, 2019 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate in a fireside chat
-
Lilly Announces Webcast to Discuss ADA Presentations and Diabetes Portfolio
INDIANAPOLIS , May 29, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 10, 2019 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's 79th Scientific Sessions in San Francisco, California .
-
Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
INDIANAPOLIS , May 28, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation , a company focused on developing non-opioid, non-addictive therapeutics for the
-
Lilly to Participate in UBS Global Healthcare Conference
INDIANAPOLIS , May 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Christi Shaw , president of Lilly Bio-Medicines, will participate in a fireside chat at 9:30 a.m., Eastern Time.
-
Lilly to Participate in Bank of America Merrill Lynch Health Care Conference
INDIANAPOLIS , May 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019 . Enrique Conterno , senior vice president of Lilly and president of Lilly Diabetes and Lilly USA , will
-
Lilly Declares Second-Quarter 2019 Dividend
INDIANAPOLIS , May 6, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2019 of $0.645 per share on outstanding common stock. The dividend is payable June 10, 2019 , to shareholders of record at the close of business
-
Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance to Reflect Disposition of Elanco Animal Health
- Revenue in the first quarter of 2019 grew 3 percent, driven by 7 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Verzenio, Basaglar, Olumiant, Jardiance, Cyramza and Emgality represented approximately 39 percent of revenue and delivered strong volume
-
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit
INDIANAPOLIS , April 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in the company's favor regarding patentability of the vitamin regimen for Alimta® (pemetrexed for injection).
-
Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China
INDIANAPOLIS , April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor ® and Vancocin ® , as well as a manufacturing facility in Suzhou, China that produces
-
Lilly and Local Partners Launch Diabetes Prevention and Management Pilot in Three Underserved Neighborhoods in Indianapolis
New $7 Million Intervention Brings Global Approach to U.S., Leveraging the Expertise of Fairbanks School of Public Health and Other Local Partners INDIANAPOLIS , May 1, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Indiana University's Richard M.
-
Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death
DANVILLE, Pa. , RIDGEFIELD, Conn. and INDIANAPOLIS , Sept. 25, 2017 /PRNewswire/ -- In an effort to improve health outcomes of people with type 2 diabetes, Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company (NYSE: LLY), today announced a major
-
Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS , July 31, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company ( NYSE : LLY) today announced that the companies will support an American College of Cardiology (ACC) program focused on driving quality improvement in cardiology and addressing the
-
Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom
Bassett encourages people with type 2 diabetes and their loved ones to take and share the Heart You Quiz to learn more about the No. 1 killer of people with this conditionFor every person who signs up to receive more information at ForYourSweetHeart.com, $1 will be donated to leading patient advocacy organizations to further their missions of educating and empowering people with diabetes and hear…
-
Eli Lilly and Company Sponsors Arthritis Foundation 'Living Your Yes With RA,' an Initiative to Provide Resources for the Rheumatoid Arthritis Community
National, three-year program kicks off in 15 cities across the U.S.
-
Lilly's First Volunteer Teams of 2016 Depart in May for Thailand and Ghana
One hundred employees from Lilly operations worldwide will volunteer throughout the year in impoverished communities across 10 countries through Connecting Hearts Abroad
-
Lilly and United Way Celebrate Deepening Partnership, Community Impact
Lilly presents United Way with $13 million to help families and strengthen communities
-
Diabetes Scholars Foundation Announces 2015 Scholarship Recipients
Lilly Diabetes donation helps 21 students attend college through Tomorrow's Leaders Scholarships
-
Olympian Kris Freeman and NASCAR Driver Ryan Reed to Share Their Courageous Stories with Children Who Have Type 1 Diabetes
Lilly Diabetes ambassadors return for 11th annual summer camp tour